Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: A phase I trial in metastatic melanoma

被引:62
作者
Duval, L
Schmidt, H
Kaltoft, K
Fode, K
Jensen, JJ
Sorensen, SM
Nishimura, MI
von der Maase, H
机构
[1] Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus C, Denmark
[2] Aarhus Univ Hosp, Dept Radiol, DK-8000 Aarhus, Denmark
[3] Univ Aarhus, Dept Human Genet, Aarhus, Denmark
[4] Univ Chicago, Dept Surg, Chicago, IL 60637 USA
关键词
D O I
10.1158/1078-0432.CCR-05-1485
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: We did a phase I dose-escalation trial to evaluate the feasibility and safety of intratumoral injections of C Cure 709, an allogeneic, continuous CTL cell line that, restricted by HLA-A2, recognizes MART-1-positive tumor cells through transduction with a T-cell receptor encoding gene. Experimental Design: Cells were administered intratumorally in four dose levels ranging from 10(8) to 10(9) cells/d on days 1, 4, 7, 10, 14, and 28 of each treatment cycle to patients with metastatic melanoma. Main inclusion criteria were HLA-A2 tissue type, MART-1-positive tumor cells, and metastases suitable for ultrasound-guided injections. Patients were assessed for toxicity and response. Three to six patients were treated per dose level. Patients without progressive disease were offered up to three treatment cycles. Results: Fifteen patients received a total of 24 treatment cycles with a total of 266 injections of C Cure 709. Toxicity was minor to moderate and most common injection site reactions were fever, fatigue, nausea/vomiting, and arthralgia/myalgia. Side effects disappeared in general within 24 hours. Toxicity was not dose dependent. One patient obtained a partial response, encompassing both metastases used and not used for intratumoral injections. Remaining patients did not achieve an overall response. In addition, we observed local regression of metastases used for injection in two patients and of metastases not used for injection in one patient. Conclusion: Intratumoral injections of C Cure 709 are feasible, safe, and capable of inducing tumor regression. Further investigation in a phase II setting is warranted.
引用
收藏
页码:1229 / 1236
页数:8
相关论文
共 39 条
[1]   ADOPTIVE IMMUNOTHERAPY OF ADVANCED MELANOMA PATIENTS WITH INTERLEUKIN-2 (IL-2) AND TUMOR-INFILTRATING LYMPHOCYTES SELECTED INVITRO WITH LOW-DOSES OF IL-2 [J].
ARIENTI, F ;
BELLI, F ;
RIVOLTINI, L ;
GAMBACORTIPASSERINI, C ;
FURLAN, L ;
MASCHERONI, L ;
PRADA, A ;
RIZZI, M ;
MARCHESI, E ;
VAGLINI, M ;
PARMIANI, G ;
CASCINELLI, N .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1993, 36 (05) :315-322
[2]   Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 [J].
Brentjens, RJ ;
Latouche, JB ;
Santos, E ;
Marti, F ;
Gong, MC ;
Lyddane, C ;
King, PD ;
Larson, S ;
Weiss, M ;
Rivière, I ;
Sadelain, M .
NATURE MEDICINE, 2003, 9 (03) :279-286
[3]   Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation [J].
Childs, R ;
Chernoff, A ;
Contentin, N ;
Bahceci, E ;
Schrump, D ;
Leitman, S ;
Read, EJ ;
Tisdale, J ;
Dunbar, C ;
Linehan, WM ;
Young, NS ;
Barrett, AJ ;
Clave, E ;
Epperson, D ;
Mayo, V .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (11) :750-758
[4]  
Clay TM, 1999, J IMMUNOL, V163, P507
[5]  
COLE DJ, 1995, CANCER RES, V55, P748
[6]   Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation [J].
Collins, RH ;
Shpilberg, O ;
Drobyski, WR ;
Porter, DL ;
Giralt, S ;
Champlin, R ;
Goodman, SA ;
Wolff, SN ;
Hu, W ;
Verfaillie, C ;
List, A ;
Dalton, W ;
Ognoskie, N ;
Chetrit, A ;
Antin, JH ;
Nemunaitis, J .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :433-444
[7]   TRANSFER OF SPECIFICITY BY MURINE ALPHA-T-CELL AND BETA-T-CELL RECEPTOR GENES [J].
DEMBIC, Z ;
HAAS, W ;
WEISS, S ;
MCCUBREY, J ;
KIEFER, H ;
VONBOEHMER, H ;
STEINMETZ, M .
NATURE, 1986, 320 (6059) :232-238
[8]  
Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514
[9]   Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma [J].
Dudley, ME ;
Wunderlich, J ;
Nishimura, MI ;
Yu, D ;
Yang, JC ;
Topalian, SL ;
Schwartzentruber, DJ ;
Hwu, P ;
Marincola, FM ;
Sherry, R ;
Leitman, SF ;
Rosenberg, SA .
JOURNAL OF IMMUNOTHERAPY, 2001, 24 (04) :363-373
[10]   Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation [J].
Goulmy, E ;
Schipper, R ;
Pool, J ;
Blokland, E ;
Falkenburg, JHF ;
Vossen, J ;
Gratwohl, A ;
Vogelsang, GB ;
vanHouwelingen, HC ;
vanRood, JJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :281-285